Opin­ion: Pric­ing in­fo with new drug ap­provals: Time for trans­paren­cy

For years Con­gress has raised con­cerns with the way some drug­mak­ers pay to de­lay gener­ic ver­sions of their brand­ed block­busters, as well as oth­er patent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.